Predictive value of peripheral blood CD34-positive cell count for the stem cell mobilization effect of plerixafor in patients with multiple myeloma
10.3760/cma.j.cn115356-20210804-00168
- VernacularTitle:多发性骨髓瘤患者外周血CD34阳性细胞计数对普乐沙福干细胞动员效果的预测价值
- Author:
Zhongqing LI
1
;
Lin LUO
;
Li ZHOU
;
Qiaochuan LI
;
Lianjin LIU
;
Lingling SHI
;
Yibin YAO
;
Yuling XU
;
Rongrong LIU
;
Yinghua CHEN
;
Yanye LIU
;
Jun LUO
Author Information
1. 广西医科大学第一附属医院血液科，南宁 530021
- Keywords:
Multiple myeloma;
Plerixafor;
CD34-positive cell count;
Hematopoietic stem cell mobilization;
Autologous hematopoietic stem cell transplantation
- From:
Journal of Leukemia & Lymphoma
2022;31(5):282-285
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the predictive value of peripheral blood CD34-positive cell count for the stem cell mobilization effect of plerixafor in patients with multiple myeloma (MM).Methods:The clinical data of 12 MM patients who used plerixafor for stem cell mobilization in the First Affiliated Hospital of Guangxi Medical University from December 2019 to February 2021 were retrospectively analyzed. The changes of peripheral blood CD34-positive cell count and the collection status of stem cell in all patients before and after the mobilization of plerixafor were analyzed.Results:Twelve patients were included in this study. These patients were in international staging system (ISS) stage Ⅱ-Ⅲ, and the induction therapy was mainly VRD regimen. The CD34-positive cell count was increased after the use of plerixafor in all patients no matter which mobilization strategies were used before plerixafor. The CD34-positive cell count was 3.63/μl (0.72-13.53/μl) and 32.11/μl (8.52-53.68/μl) before and after the use of plerixafor, and the difference was statistically significant ( Z = -0.40, P<0.001); the median increasing time was 11.50 times (1.61-23.71 times). The mobilization failure occurred in 1 patient. The CD34-positive cell count in his blood was less than 1/μl before the use of plerixafor; though increased 11.83 times after the use of plerixafor, the CD34-positive cell count was still less than 10/μl. Pearson analysis showed that among the patients with CD34-positive cell count less than 4/μl before the use of plerixafor, there was a positive correlation in peripheral blood CD34-positive cell count before and after the use of plerixafor ( r = 0.80, P = 0.032). Conclusions:The peripheral blood CD34-positive cell count has a certain predictive value for the stem cell mobilization effect of plerixafor in MM patients.
